Literature DB >> 25551530

Atypical hyperplasia of the breast--risk assessment and management options.

Lynn C Hartmann1, Amy C Degnim, Richard J Santen, William D Dupont, Karthik Ghosh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25551530      PMCID： PMC4347900          DOI： 10.1056/NEJMsr1407164

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  69 in total

1.  Exemestane for breast-cancer prevention in postmenopausal women.

Authors:  Paul E Goss; James N Ingle; José E Alés-Martínez; Angela M Cheung; Rowan T Chlebowski; Jean Wactawski-Wende; Anne McTiernan; John Robbins; Karen C Johnson; Lisa W Martin; Eric Winquist; Gloria E Sarto; Judy E Garber; Carol J Fabian; Pascal Pujol; Elizabeth Maunsell; Patricia Farmer; Karen A Gelmon; Dongsheng Tu; Harriet Richardson
Journal:  N Engl J Med       Date:  2011-06-04       Impact factor: 91.245

Review 2.  Benign breast disorders.

Authors:  Richard J Santen; Robert Mansel
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

3.  Results of MRI screening for breast cancer in high-risk patients with LCIS and atypical hyperplasia.

Authors:  Elisa Rush Port; Anna Park; Patrick I Borgen; Elizabeth Morris; Leslie L Montgomery
Journal:  Ann Surg Oncol       Date:  2007-01-07       Impact factor: 5.344

4.  American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography.

Authors:  Debbie Saslow; Carla Boetes; Wylie Burke; Steven Harms; Martin O Leach; Constance D Lehman; Elizabeth Morris; Etta Pisano; Mitchell Schnall; Stephen Sener; Robert A Smith; Ellen Warner; Martin Yaffe; Kimberly S Andrews; Christy A Russell
Journal:  CA Cancer J Clin       Date:  2007 Mar-Apr       Impact factor: 508.702

Review 5.  Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.

Authors:  M H Gail; J P Costantino; J Bryant; R Croyle; L Freedman; K Helzlsouer; V Vogel
Journal:  J Natl Cancer Inst       Date:  1999-11-03       Impact factor: 13.506

6.  Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.

Authors:  Trevor J Powles; Sue Ashley; Alwynne Tidy; Ian E Smith; Mitch Dowsett
Journal:  J Natl Cancer Inst       Date:  2007-02-21       Impact factor: 13.506

7.  Breast cancer incidence in a cohort of women with benign breast disease from a multiethnic, primary health care population.

Authors:  Maria J Worsham; Judith Abrams; Usha Raju; Alissa Kapke; Mei Lu; Jingfang Cheng; Donna Mott; Sandra R Wolman
Journal:  Breast J       Date:  2007 Mar-Apr       Impact factor: 2.431

8.  Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.

Authors:  Jack Cuzick; John F Forbes; Ivana Sestak; Simon Cawthorn; Hisham Hamed; Kaija Holli; Anthony Howell
Journal:  J Natl Cancer Inst       Date:  2007-02-21       Impact factor: 13.506

9.  Benign breast disease and the risk of breast cancer.

Authors:  Lynn C Hartmann; Thomas A Sellers; Marlene H Frost; Wilma L Lingle; Amy C Degnim; Karthik Ghosh; Robert A Vierkant; Shaun D Maloney; V Shane Pankratz; David W Hillman; Vera J Suman; Jo Johnson; Cassann Blake; Thea Tlsty; Celine M Vachon; L Joseph Melton; Daniel W Visscher
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

10.  Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.

Authors:  Jack Cuzick; Ivana Sestak; John F Forbes; Mitch Dowsett; Jill Knox; Simon Cawthorn; Christobel Saunders; Nicola Roche; Robert E Mansel; Gunter von Minckwitz; Bernardo Bonanni; Tiina Palva; Anthony Howell
Journal:  Lancet       Date:  2013-12-12       Impact factor: 79.321
View more
  73 in total

1.  ERβ expression and breast cancer risk prediction for women with atypias.

Authors:  Tina J Hieken; Jodi M Carter; John R Hawse; Tanya L Hoskin; Melanie Bois; Marlene Frost; Lynn C Hartmann; Derek C Radisky; Daniel W Visscher; Amy C Degnim
Journal:  Cancer Prev Res (Phila)       Date:  2015-08-14

2.  Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women.

Authors:  Amy C Degnim; William D Dupont; Derek C Radisky; Robert A Vierkant; Ryan D Frank; Marlene H Frost; Stacey J Winham; Melinda E Sanders; Jeffrey R Smith; David L Page; Tanya L Hoskin; Celine M Vachon; Karthik Ghosh; Tina J Hieken; Lori A Denison; Jodi M Carter; Lynn C Hartmann; Daniel W Visscher
Journal:  Cancer       Date:  2016-06-28       Impact factor: 6.860

3.  Breast cancer risk by the extent and type of atypical hyperplasia.

Authors:  Amy C Degnim; Daniel W Visscher; Derek C Radisky; Marlene H Frost; Robert A Vierkant; Ryan D Frank; Stacey J Winham; Celine M Vachon; William D Dupont; Lynn C Hartmann
Journal:  Cancer       Date:  2016-06-28       Impact factor: 6.860

4.  Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

Authors:  A S Coates; E P Winer; A Goldhirsch; R D Gelber; M Gnant; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2015-05-04       Impact factor: 32.976

5.  Surgical implications and variability in the use of the flat epithelial atypia diagnosis on breast biopsy specimens.

Authors:  Laura S Samples; Mara H Rendi; Paul D Frederick; Kimberly H Allison; Heidi D Nelson; Thomas R Morgan; Donald L Weaver; Joann G Elmore
Journal:  Breast       Date:  2017-05-03       Impact factor: 4.380

6.  Addressing barriers to uptake of breast cancer chemoprevention for patients and providers.

Authors:  Katherine D Crew
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

7.  Clinicopathologic features of breast cancers that develop in women with previous benign breast disease.

Authors:  Daniel W Visscher; Marlene H Frost; Lynn C Hartmann; Ryan D Frank; Robert A Vierkant; Ann E McCullough; Stacey J Winham; Celine M Vachon; Karthik Ghosh; Kathleen R Brandt; Ann M Farrell; Yaman Tarabishy; Tina J Hieken; Tufia C Haddad; Ruth A Kraft; Derek C Radisky; Amy C Degnim
Journal:  Cancer       Date:  2015-10-29       Impact factor: 6.860

8.  CXCL1 Derived from Mammary Fibroblasts Promotes Progression of Mammary Lesions to Invasive Carcinoma through CXCR2 Dependent Mechanisms.

Authors:  Shira Bernard; Megan Myers; Wei Bin Fang; Brandon Zinda; Curtis Smart; Diana Lambert; An Zou; Fang Fan; Nikki Cheng
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-08-09       Impact factor: 2.673

9.  Diagnostic concordance among pathologists interpreting breast biopsy specimens.

Authors:  Joann G Elmore; Gary M Longton; Patricia A Carney; Berta M Geller; Tracy Onega; Anna N A Tosteson; Heidi D Nelson; Margaret S Pepe; Kimberly H Allison; Stuart J Schnitt; Frances P O'Malley; Donald L Weaver
Journal:  JAMA       Date:  2015-03-17       Impact factor: 56.272

10.  A survey of Canadian breast health professionals’ recommendations for high-risk benign breast disease

Authors:  Coralea Kappel; Jean Seely; James Watters; Angel Arnaout; Erin Cordeiro
Journal:  Can J Surg       Date:  2019-10-01       Impact factor: 2.089
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.